- Home
- ECX vs YMAB Comparison
ECX vs YMAB Comparison
Compare ECX & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- YMAB
- Stock Information
- Founded
- ECX 2017
- YMAB 2015
- Country
- ECX China
- YMAB United States
- Employees
- ECX N/A
- YMAB N/A
- Industry
- ECX EDP Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ECX Technology
- YMAB Health Care
- Exchange
- ECX Nasdaq
- YMAB Nasdaq
- Market Cap
- ECX 584.9M
- YMAB 631.1M
- IPO Year
- ECX N/A
- YMAB 2018
- Fundamental
- Price
- ECX $1.79
- YMAB $14.20
- Analyst Decision
- ECX
- YMAB Strong Buy
- Analyst Count
- ECX 0
- YMAB 8
- Target Price
- ECX N/A
- YMAB $21.38
- AVG Volume (30 Days)
- ECX 58.7K
- YMAB 229.5K
- Earning Date
- ECX 11-07-2024
- YMAB 11-11-2024
- Dividend Yield
- ECX N/A
- YMAB N/A
- EPS Growth
- ECX N/A
- YMAB N/A
- EPS
- ECX N/A
- YMAB N/A
- Revenue
- ECX $705,233,730.00
- YMAB $86,546,000.00
- Revenue This Year
- ECX N/A
- YMAB $11.00
- Revenue Next Year
- ECX $39.50
- YMAB $19.38
- P/E Ratio
- ECX N/A
- YMAB N/A
- Revenue Growth
- ECX 28.62
- YMAB 1.84
- 52 Week Low
- ECX $0.96
- YMAB $4.69
- 52 Week High
- ECX $4.68
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- ECX 47.73
- YMAB 53.95
- Support Level
- ECX $1.73
- YMAB $14.04
- Resistance Level
- ECX $1.92
- YMAB $15.10
- Average True Range (ATR)
- ECX 0.08
- YMAB 0.72
- MACD
- ECX -0.02
- YMAB 0.06
- Stochastic Oscillator
- ECX 24.00
- YMAB 62.34
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services primarily in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.